Some parameters of physical fitness in children after treatment of a malignant tumour with antracyclines with cardioprotection;Nektere parametry telesne zdatnosti u deti po terapii zhoubneho nadoru antracykliny s kardioprotekci

Cesko-Slovenska Pediatrie

Volumn 52, Issue 9, 1997, Pages 679-682

  Hrstkova H ^a   Novotny J ^b   Necas J ^c  

^a UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^b ST ANNE S UNIVERSITY HOSPITAL   (Czech Republic)

^c Centre for Cardiovascular Surgery and Transplantation   (Czech Republic)

Author keywords

Antracyclines; Cardioprotection; Physical fitness; Spiroergometry

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; RAZOXANE;

ADOLESCENT; ARTICLE; BICYCLE ERGOMETRY; CLINICAL ARTICLE; DRUG EFFECT; FITNESS; HEART MUSCLE OXYGEN CONSUMPTION; HEART PROTECTION; HUMAN; MALIGNANT NEOPLASTIC DISEASE; SCHOOL CHILD; TREATMENT OUTCOME;

EID: 0030700931     PISSN: 00692328     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Elbl, L., Vášová, I., Chaloupka, V., Hájek, R., Vorlíček, J.: Zhodnocení kardioprotektivního účinku bispiperazinedionu (ICRF-187-Cardioxane) u nemocných léčených kardioxany. Vnitř. Lék., 42, 1996, č. 4, s. 268-273.
2. European Society of Cardiology and North Americxan Society of Pacing and Electrophysiology: Heart rate variability. Standards of measurement, physiological interpretation, and clinical use. Circulation, 93, 1996, s. 1043-1065.
3. Fryer, Ch. H., Rogers, P. C.: Hodgkin's disease. II. Treatment and complications. In: Pochedly, C.: Neoplastic Disease of Childhood. Vol. 1. Harwood Academic Publishers GmbH 1994, s. 673-690.
4. Hancock, S. L., Donaidson, S. S.: Radiation, related heart disease: Risk after treatment of Hodgkin's disease during childhood and adolescence. In: Bricker, J. T. et al. (Eds.): Cardiac Toxicity after Treatment for Childhood. Wiley-Liss Inc. 1993, s. 35-43.
5. Hausdorf, G.: Late effects of anthracykline therapy in childhood: Evaluation and current therapy. In: Bricker, J. T. et al. (Eds.): Cardiac Toxicity after Treatment for Childhood. Wiley-Liss Inc. 1993, s. 45-53.
6. Jakacki, R. I., Larsen, R. L., Barber, G., Goldwein, J. W., Silber, H.: Cardiac function following cardiotoxic therapy during childhood assessing the damage. In: Bricker, J. T. et al. (Eds.): Cardiac Toxicity after Treatment for Childhood. Wiley-Liss Inc. 1993, s. 8-94.
7. Lang, D., Holger, F., Binswanger, J., Adelsfinger, G., Hartmann, W.: Later effects of anthracykline therapy in childhood in relation to the function of the heart at rest and under physical stress. Eur. J. Pediatr., 154, 1995, s. 340-345.
8. Lentner, C. et al.: Geigy Scientific Tables. Basel, Ciba-Geigy Ltd. 1990. 96 s.
9. Lipshultz, S. E., Colan, S. D., Gelber, R. D., Perez-Atayde, A. R., Sallan, S. E., Sanders, S. P.: Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. New Engl. J. Med., 324, 1991, s. 808-815.
10. Steinherz, L. J., Steinherz, P. G.: Anthracykoine - related cardiac damage. In: Bricker, J. T. et al. (Eds.): Cardiac Toxicity after Treatment for Childhood. Wiley-Liss Inc. 1993, s. 63-72.
11. Šnajdauf, J., Fryč, M., Kabelka, M., Šintáková, B., Koutecký, J., Ganevová, M., Kodet, R., Mužíková, V., Zítková, M.: Zkušenosti s léčbou expanzivních procesů mediastina v dětském věku. Čs. Pediat., 49, 1994, č. 11, s. 643-646.
12. Švihovec, J.: Pharmindex Kompendium. Medi Media 1995.
13. Turner-Gomez, S. O., Heigenhauser, L. C. G. J. F., Pai, M., Barr, R.: Cardiorespiratory status after treatment for acute lymphoblastic leukemia. Med. Pediat. Oncol., 26, 1966, s. 160-165.
14. Yeung, S. T., Yoong, C., Spink, J., Galbraith, A., Smith, P. J.: Functional myocardial impairment in children treated with anthracylines for cancer. Lancet, 6, 1991, s. 816-818.